1-5 of 5
ccaat/enhancer binding protein alpha
Close
Sort by
Journal Articles

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter

Gregory W. Roloff, Elizabeth A. Griffiths
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 35–44.
https://doi.org/10.1182/asheducation-2018.1.35
Published: 2018
Journal Articles

Intermediate-risk acute myeloid leukemia therapy: current and future

Konstanze Döhner, Peter Paschka
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 34–43.
https://doi.org/10.1182/asheducation.V2014.1.34.3882398
Published: 2014
Journal Articles

High Cytogenetic or Molecular Genetic Risk Acute Myeloid Leukemia

Elihu Estey
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 474–480.
https://doi.org/10.1182/asheducation-2010.1.474
Published: 2010
Journal Articles

New Prognostic Markers in Acute Myeloid Leukemia: Perspective from the Clinic

James M. Foran
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 47–55.
https://doi.org/10.1182/asheducation-2010.1.47
Published: 2010
Journal Articles

Implication of the Molecular Characterization of Acute Myeloid Leukemia

Hartmut Döhner
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2007) 2007 (1): 412–419.
https://doi.org/10.1182/asheducation-2007.1.412
Published: 2007